Foreign generics will hurt local pharmaceutical sector

Published: 2010-12-14 07:00:00

Updated: 2010-12-14 07:00:00

There are growing concerns over the movement of foreign generic makers, such as Rabaxy and Teva, to make inroads into the Korean market if a U.S.-Korea free trade agreement goes through.

This worst-case scenario, if realized, would sharply undermine the domestic pharmaceutical sector, and a ma...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK